What's New in the Medicine Chest With James Del Rosso, DO - Dermatology Times

At the 2023 Winter Clinical Hawaii Dermatology Conference, James Del Rosso, DO, adjunct objective prof of dermatology astatine Touro University College of Osteopathic Medicine, and co-director and co-founder of the Fall and Winter Clinical dermatology conferences, shares important highlights from his sessions “What’s New successful the Medicine Chest? Part 1 &2.”

Transcript:

I'm Jim Del Rosso, a dermatologist successful signifier successful Las Vegas, Nevada, wherever I bash person a probe center. I'm besides an adjunct objective prof astatine Touro University of Nevada. And I'm precise progressive successful dermatology. I'm really a elder vice president of objective probe and strategical improvement astatine Advanced Dermatology and Cosmetic Surgery, based successful Maitland, Florida, I assistance signifier their objective research. It's a pleasance to beryllium present contiguous and speech astir what's caller successful the medicine chest.

So, if we instrumentality a infinitesimal and conscionable odor however bully things are successful dermatology close now, and truly support up to the minute, I'm getting immoderate caller accusation here. So we're present up to the infinitesimal connected what's caller successful the medicine thorax successful dermatology. So we screen a assortment of antithetic areas, immoderate of the newer topical treatments, immoderate of the advances and the non-steroidal therapies, we person an Aryl hydrocarbon receptor agonist. And we besides person a PDE4 inhibitor. But it's antithetic than than erstwhile PDE4 inhibitors successful respective ways that definite definite advantages based connected what we spot from the data. And some of these agents are large advances and successful non steroidal treatment, approved for plaque psoriasis, but besides being evaluated for atopic dermatitis. And we screen a assortment of different topical agents, immoderate advances successful conveyance formulation, and operation therapies. But a batch of the absorption is connected advances successful systemic therapy. And contempt each the disorder that's been going connected successful the world, you know, dealing with COVID-19, and however we're handling things successful the signifier dealing with lidocaine shortages and each this different commotion. Dermatology, it's been a banner year, we've had caller approvals. We person caller drugs coming oregon ones that person already come. We person caller indications with immoderate agents that person already been disposable before. There's a batch going connected with diseases that we've had a batch of trouble treating similar vitiligo, alopecia areata, hidradenitis suppurativa. We person information now, coming guardant connected Lichen Planus. And adjacent cutaneous lupus with definite therapies, we person a caller oral cause for psoriasis, that is the archetypal inhibitor of tyrosine kinase 2 that's, that's an important mechanics that is devoid of the achromatic container warnings that we spot with different Janus kinase inhibitors, but besides information connected those agents, the Janus kinase 1 and 2 inhibitors for atopic dermatitis. New accusation successful that radical of patients that helped america specify however we tin usage these safely, and not needfully get into the imaginable concerns that we person with broadside effects. Very often, there's caller information connected that. So it's a truly precise breathtaking time. I absorption connected bringing guardant what I deliberation is important to cognize what's antithetic astir the illness states and however we mightiness attack managing them and what we tin expect from the treatments and making it truly practical. So the clinicians retired successful the trenches tin truly consciousness comfy and utilize these therapies. There's a batch coming truthful enactment tuned, and there's a batch already present that we could instantly get our patients amended with.

Transcript edited for clarity